JUBLPHARMA - Swing Trade Analysis with AI Signals

Last Updated Time : 19 Sept 25, 2:15 pm

Swing Trade Rating: 2.5

💊 Swing Trade Analysis: JUBLPHARMA (Jubilant Pharmova)

JUBLPHARMA shows signs of technical stability but is fundamentally weak and highly overvalued, making it a poor candidate for swing trading at current levels.

✅ Positives

Technical Support: Price ₹1,115 is slightly above both 50-DMA (₹1,105) and 200-DMA (₹1,043), suggesting a short-term base.

MACD (4.43): Positive — indicates mild bullish momentum.

Volume: Above weekly average — shows increased interest.

Institutional Sentiment: DII holdings rose significantly (+2.47%), a strong vote of confidence.

⚠️ Negatives

Valuation: P/E of 855 vs industry average of 33.4 is extremely inflated; PEG ratio of -26.1 confirms unsustainable pricing.

Profitability: ROCE (2.91%) and ROE (1.04%) are very weak — poor capital efficiency.

Earnings Volatility: PAT dropped from ₹0.90 Cr to ₹4.10 Cr, but overall quarterly variation is negative.

Book Value: ₹146 vs current price ₹1,115 — minimal intrinsic support.

RSI (54.4): Neutral — no strong momentum signal.

🎯 Optimal Entry Price

Buy Zone: ₹1,070–₹1,090

Near 200-DMA; only consider entry if MACD continues to rise and RSI moves above 60.

🚪 Exit Strategy (If Holding)

Target Exit: ₹1,180–₹1,200

Near short-term resistance; exit if RSI approaches 70 or MACD flattens.

Stop Loss: ₹1,040

Below this level, trend support breaks.

⚖️ Verdict

JUBLPHARMA is a weak swing trade candidate due to extreme valuation and poor fundamentals. Only suitable for short-term technical plays with tight risk controls. Avoid unless momentum strengthens significantly.

Edit in a page